StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries Manufacturing & R&D Facilities — United States by Year

Teva Pharmaceutical Industries Manufacturing & R&D Facilities — United States: 10 in FY2025, down 23.1% from a year earlier.

Latest, FY2025
10
Period ended Dec 31, 2025
Change on a year earlier
-23.1%
13 in FY2024
History
3 years
Since FY2017
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| United States | 10 | 1,891”

Source: Form 10-K (0001193125-26-034532) ↗

Reported in SEC Form 10-K (Item 2. Properties).

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedManufacturing & R&D Facilities — United StatesYear on yearSource
FY2025Dec 31, 202510-23.1%Form 10-K (0001193125-26-034532) ↗
FY2024Dec 31, 202413–Form 10-K (0001193125-25-020826) ↗
FY2017Dec 31, 201717–Form 10-K (0001193125-18-039076) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Manufacturing & R&D Facilities — United States, annual FY2017–FY2025 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/fac-us-count

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?